33 results about "Core peptide" patented technology

The invention provides isolated agents having a core peptide selected from the group consisting of Core peptides 5 through 39 and 42 through 55, wherein the agent derepresses an IAP-inhibited caspase. Also provided is an isolated agent having a core structure selected from any of the structures shown in FIGS. 5, 9, 10, 14B, 21-24 and 48, a core structure selected from the group of TPI 759, TPI 882, TPI 914 or TPI 927; and a core structure from a library selected from TPI 1391, TPI 1349, TPI 1396, TPI 1509, TPI 1540, TPI 1400, TPI 792, TPI 1332, TPI 1567, TPI 1576 and TPI 1577, wherein the agent derepresses an IAP-inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase.

The invention provides isolated agents having a core peptide selected from the group consisting of Core peptides 5 through 39 and 42 through 55, wherein the agent derepresses an IAP-inhibited caspase. Also provided is an isolated agent having a core structure selected from any of the structures shown in FIGS. 5, 9, 10, 14B, and 21-24 wherein said agent derepresses an IAP-inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The method consists of contacting an IAP-inhibited caspase with an effective amount of an agent to derepress an IAP-inhibited caspase, the agent having a core motif selected from the group consisting of a core peptide having a sequence set forth in any of Core peptides 4 through 39 and 42 through 55, and a core structure selected from the group consisting of TPI759, TPI882, TPI914 or TPI927. The methods of the invention also can be used for promoting apoptosis in a cell and for reducing the severity of a pathology characterized by reduced levels of apoptosis. Methods for identifying agents that derepress an IAP-inhibited caspase are also provided.

The invention comprises systems, methods and arrays for identification and optimization of novel peptide binders to protein targets. Embodiments include steps of peptide binder discovery, core peptide maturation, N-terminal and C-terminal extension and kinetics analysis of the final peptide binder.

The present disclosure provides smart contrast agents for transition metals and a method of using the same. The smart contrast agents include a core peptide and a first labeling group attached to a first end of the core peptide. The smart contrast agents can also include a second labeling group attached to a second end of the core peptide. The core peptide can bind to transition metals, and can be homologous to a fragment selected from the extended octarepeat region of a prion protein.

HBV surface antigen particles, prepared by recombinant DNA technology are described, said particles being composed of epitopes from the group of surface peptides and/or core peptide of non-A, non-B hepatitis virus, hepatitis virus A and/or hepatitis virus B. Respective particles are especially characterized by a composition of different epitopes selected from pre-S and S peptides. There are also described DNA-sequences, plasmids and cell lines coding for respective HBV surface antigen particles as well as a new vaccine containing the same.

The invention provides isolated agents having a core peptide selected from the group consisting of Core peptides 5 through 39 and 42 through 55, wherein the agent derepresses an IAP-inhibited caspase. Also provided is an isolated agent having a core structure selected from any of the structures shown in FIGS. 5, 9, 10, 14B, and 21-24, a core structure selected from the group of TPI 759, TPI 882, TPI 914 or TPI 927; and a core structure from a library selected from TPI 1391, TPI 1349, TPI 1396, TPI 1509, TPI 1540, TPI 1400, TPI 792 and TPI 1332, wherein the agent derepresses an IAP-inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase.

The invention discloses novel lysyl endopeptidase. A suitable flexible linker peptide is connected to an enzyme core peptide, a histidine label and an arginine tail end, while the original enzymatic activity is maintained, nanogram-level residual enzyme in a sample is detected by an ELISA method, and furthermore, novel lysyl endopeptidase sterling is obtained by purification of an ion exchange layer. The invention further provides a preparation method of the lysyl endopeptidase, after 1L of fermentation broth is purified, the recycling amount of 107 mg of the novel lysyl endopeptidase sterlingcan be achieved, and the novel lysyl endopeptidase has industrial potential.

The invention discloses novel lysyl endopeptidase. An enzyme core peptide is connected with histidine tags through an appropriate flexible linker peptide, so that nanogram residual enzyme in a samplecan be detected by an ELISA (enzyme-linked immunosorbent assay) method; and total activity of wild lysyl endopeptidase is ensured. At the same time, the invention further provides a preparation methodof the lysyl endopeptidase. Compared with a gene engineering modification and fermentation technology, the preparation method has the benefit of high yield; a recovery amount of 857mg novel lysyl endopeptidase can be obtained after purification of 1L fermentation liquid; and the method has an industrial potential.

The invention relates to the field of bioengineering, in particular to a screening method of wool thiopeptide, a cell-free protein synthesis system and the wool thiopeptide. The screening method comprises the following steps of (1) determining candidate wool thiopeptide based on a sequence of reference wool thiopeptide; (2) connecting the core peptide coding sequence of the candidate wool thiopeptide with a leader peptide sequence, and connecting the obtained connection product with a vector, so as to obtain a recombinant expression vector; (3) carrying out contact reaction on the recombinantexpression vector, a cell extract and an amino acid premix solution to obtain the candidate wool thiopeptide, and (4) performing screening to obtain the target wool thiopeptide based on different properties of the candidate wool thiopeptide. According to the method, the target wool thiopeptide can be conveniently and quickly obtained by utilizing the cell-free protein synthesis system.

The invention discloses a divalent targeted polypeptide probe and a preparation method and application thereof. The probe comprises A) two tumor specific targeting polypeptide; B) two PEG linking arms; C) skeleton core peptide and D) fluorescence molecules. Each tumor specific targeting polypeptide is connected with the PEG linking arm via a group as shown in the formula I; the amino acid sequenceof the skeleton core peptide is KGGKG; the skeleton core peptide is coupled to the two tumor specific targeting polypeptide via the PEG linking arms; and the fluorescence molecules are connected to the skeleton core peptide via chemical bonds. According to the multivalent targeted probe FITC-2PEG9-2AP2H, two targeted ligands AP2H are coupled to the skeleton core peptide via PEG chains, the PEG chains can improve the dissolvability of the targeted polypeptide probe in an aqueous solution as well as the flexibility of the probe, and thus, the probe can identify and be combined with a target object.

The invention discloses a protein ubiquitination modification site detection method based on a high-precision mass spectrum and application, and the protein ubiquitination modification site detection method comprises the following steps: S1, constructing an in-vitro SUMOylation modification reaction system to obtain a target protein; S2, carrying out trypsin digestion on the target protein obtained in the step S1, so as to obtain a polypeptide fragment after enzyme digestion; S3, performing liquid chromatography-mass spectrometry analysis on the polypeptide obtained in the step S2 to acquire polypeptide mass spectrum data, and performing data analysis to obtain a sequence of a modification site and a core peptide fragment; S4, chemically synthesizing an isotope labeled peptide fragment sequence containing SUMOylation modification sites, and carrying out site confirmation by adopting a PRM method to determine a set of parent-daughter ion pairs; S5, detecting an endogenous modification site by using the parent-daughter ion pair established in the step S4; the SUMOylation modification refers to ubiquitination modification of the SUMO1 type.

The invention relates to a natural composite with biological activity extracted from conch, and application in the pharmaceutical field of the same, pertains to biological and pharmaceutical technical fields. The invention protects a natural composite with biological activity, preparation and application thereof. The invention is extracted from marine organism of conch, has a unique biological activity, can notably content of primotest in PADAM patient's blood.

The present invention discloses a cypemycin precursor peptide mutant and an application thereof and prepared cypemycin analogues. The mutant is prepared by mutating one or more threonines in a core peptide to serine, lysine, alanine or leucine; and/or, mutating one or two glutamines in the core peptide to glutamic acid; and/or, mutating serine in the core peptide to alanine or tyrosine; and/or, mutating valine at a 12nd and/or 21st position of a sequence shown in SEQ ID NO.1 to lysine, alanine, isoleucine, or cysteine; and/or, mutating cysteine at a 19th position of the sequence shown in the SEQ ID NO.1 to serine or tyrosine; and/or, mutating cysteine at a 33rd position and/or proline at a 36th position of a sequence shown in SEQ ID NO.2 to alanine. A series of cypemycin analogues can be prepared by using the mutant and provide a basis for screening compounds with higher activity.

The invention discloses a multifunctional anticancer nano material based on polypeptide-rare earth nanocrystals, which is characterized in that the nano material is a hydrophilic nano microsphere of polypeptide entrapped drug adriamycin and NaYF4: Yb < 3 + >, Er < 3 + > nanocrystals; wherein the hydrophobic end of the P13 peptide is combined with the medicine doxorubicin and the NaYF4: Yb < 3 + > and Er < 3 + > nanocrystalline in a non-covalent bond form to form a hydrophobic core; and the hydrophilic end of the P13 peptide is used as a targeting end to form a hydrophilic shell. According to the invention, polypeptide is used as a carrier for entrapment of drug adriamycin, and drug inhibition and a PDT method are combined to kill tumor cells in a manner of entrapment of NaYF4: Yb < 3 + >, Er < 3 + > nanocrystals. According to the invention, a remarkable super-addition (1 + 1 > 2) effect is generated in a synergistic treatment mode, and the effect is remarkably enhanced compared with that of any single therapy; meanwhile, the multi-mode combined treatment mode can effectively overcome the multi-drug resistance of the tumor; in addition, the defect that the drug loading system cannot be subjected to fluorescence tracking due to the fact that the polypeptide has no fluorescence characteristic is overcome.

The invention discloses a polypeptide analogue and a preparation method and application thereof, a core peptide sequence of the polypeptide analogue is OA-GL12, and the core peptide is modified by one or more of the following steps: 1) extending at the N terminal of the core peptide, extending peptide is Cys, and the extending peptide Cys and the core peptide Cys form a disulfide bond; (2) carrying out O-glycosylation modification on the core peptide; 3) carrying out fatty acid modification on the N terminal of the core peptide; and 4) fusing SYN-AKE at the tail end of the core peptide C. The Cyclic-GC12 subjected to cyclization modification is not easy to oxidize and is good in stability; glyco-GC12 subjected to glycosylation modification has better skin absorptivity, so that the Glyco-GC12 can be used for preparing the skin care product; the transdermal effect of the long-chain fatty acid modified Pal-GC12 is enhanced, and the stability is better; the SYN-AKE-GC12 fused by the SYN-AKE-GC12, the SYN-AKE-GC12, the SYN-AKE-GC12 and the

The invention relates to HLA-restricted CD4<+> T cell epitope immunodominant peptide and core peptide of Helicobacter pylori Lpp20, which have structures represented as the SEQ ID No.10 and SEQ ID No.30; the proper CD4<+> T cell epitopes (SEQ ID No.10 and SEQ ID No.30) in the invention are reliable and accurate; what is more, it can be evaluated that the identified epitope belongs to whether immunodominance or subdominance, which has advantages on design of epitope vaccines.

The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. The multiple antigenic agents of the invention contain at least one of a B cell determinant, a T cell determinant, or a targeting molecule attached to a core peptide composed of Lys-Gly repeats.